The significance of testosterone in the development of prostate cancer, as well as the safety of testosterone therapy (TTh) following prostate cancer treatment or in the context of active monitoring, is still debated. There were several concerns regarding taking TTH in males, especially those with a history of prostate cancer, ranging from an increased risk of cardiovascular disease to cancer development or recurrence. With many prostate cancer patients living longer lives and hypogonadism causing substantial morbidity, the decision to treat must be made with great caution. For a study, researchers examined the effects of testosterone on the prostate, as well as the efficacy and safety of exogenous testosterone in men with a history of prostate cancer. 

The improvement in quality of life associated with TTh was thoroughly studied and understood, but the case for a considerably increased risk of cancer or other bad consequences was much less. There was no evidence that there was an increased risk of prostate cancer, cancer recurrence, or cardiovascular disease. There was very little data in the context of TTh in males with high-risk prostate cancer, and TTh should be used with care.

TTh-related prostate cancer worries did not appear to be adequately supported by existing evidence. Though additional research was needed to determine the safety of TTh in men with prostate cancer, therapy of hypogonadal men with a history of CaP should be considered.